logo-loader

American Manganese's new patent application broadens scope of protection for its recycling technology

Last updated: 11:49 20 Mar 2019 EDT, First published: 06:31 20 Mar 2019 EDT

Electric car
The firm wants to become the industry leader in recycling spent electric vehicle lithium-ion batteries

American Manganese Inc (OTCMKTS:AMYZF) (CVE:AMY) has filed a new patent application covering its flagship lithium-ion battery recycling technology.

The continuation in part (C-I-P) patent now covers innovations developed by the firm over the past year, resulting from successful bench scale research and Phases 1 and 2 of the pilot plant operation on various commercial feed material collected worldwide.

READ: American Manganese gains as scrap extraction results meet critical-metal company’s expectations

British Columbia-based American Manganese has a patent-approved process for recovering metals from lithium-ion batteries such as cobalt, lithium, nickel, manganese, and aluminum.

The new patent application adds the following enhancements:

  • Recovery of graphite and carbon from ground battery concentrates
  • Treatment of fluoride originating from electrolyte solution
  • Separation of aluminum from cathode active material

"This milestone was accomplished by the support of Kemetco Research Inc, especially Norm Chow, President of Kemetco," Larry Reaugh, the president and CEO at American Manganese, told investors.

"Mr Chow has done an extraordinary job ensuring the C-I-P applications were filed prior to our being granted an official patent number on our issued patent, which we expect to receive shortly. The short time span of 13 months from which the company filed the original non-provisional application and receipt of the notice of allowance, followed by the recent filing of the C-I-P puts the company in a strong position with intellectual property, which is key to working with the Tier 1 companies in the EV and personal electronics industry."

The firm wants to become the industry leader in recycling spent electric vehicle lithium-ion batteries.

Shares in Toronto were unchanged at $0.145.

---Updates to clarify nature of the patent application--

Contact Giles at giles@proactiveinvestors.com

Follow him on Twitter@Gile 74

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 36 minutes ago